Up a level |
Vastesaeger, Nathan, Kutzbach, Abraham Garcia, Amital, Howard, Pavelka, Karel, Alicia Lazaro, Maria, Moots, Robert J ORCID: 0000-0001-7019-6211, Wollenhaupt, Juergen, Zerbini, Cristiano AF, Louw, Ingrid, Combe, Bernard et al (show 8 more authors)
(2016)
Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab.
RHEUMATOLOGY, 55 (8).
pp. 1466-1476.
Durez, Patrick, Pavelka, Karel, Alicia Lazaro, Maria, Garcia-Kutzbach, Abraham, Moots, Robert J ORCID: 0000-0001-7019-6211, Amital, Howard, Govoni, Marinella and Vastesaeger, Nathan
(2018)
Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial.
CLINICAL RHEUMATOLOGY, 37 (5).
pp. 1417-1420.
Moots, Robert J ORCID: 0000-0001-7019-6211, Xavier, Ricardo M, Mok, Chi Chiu, Rahman, Mahboob U, Tsai, Wen-Chan, Al-Maini, Mustafa H, Pavelka, Karel, Mahgoub, Ehab, Kotak, Sameer, Korth-Bradley, Joan et al (show 4 more authors)
(2017)
The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study (vol 12, e0175207, 2017).
PLOS ONE, 12 (6).
e0179308-.
Moots, Robert J ORCID: 0000-0001-7019-6211, Xavier, Ricardo M, Mok, Chi Chiu, Rahman, Mahboob U, Tsai, Wen-Chan, Al-Maini, Mustafa H, Pavelka, Karel, Mahgoub, Ehab, Kotak, Sameer, Korth-Bradley, Joan et al (show 4 more authors)
(2017)
The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
PLOS ONE, 12 (4).
e0175207-.